Also, all HempWorx products are 100% organic and non-genetically modified, and the company apparently makes all of its products right here in the United States. Moreover, the hemp used to extract the oil is grown in Kentucky, and unlike a lot of firms who claim their CBD products to be lab tested, HempWorx actually ‘walks the walk’ by publishing up-to-date details of their test results on the site (you can find them under the “HempWorx Store” tab by clicking the “CBD Oil Certification” button).
CBD is well tolerated in humans with doses up to 600 mg not resulting in psychotic symptoms (15). In the few small placebo-controlled studies performed, no significant CNS effects were noted. Oral CBD undergoes extensive first-pass metabolism via CYP3A4, with a bioavailability of 6%. Following single doses in humans, the half-life of CBD when taken orally is about 1 to 2 days.1 In vitro studies have shown that CBD is a potent inhibitor of multiple CYP isozymes, including CYP 2C and CYP3A (16, 17). Whether these in vitro observations are relevant at plasma concentrations likely to be seen in patients is unclear. In addition, given its metabolism via CYP3A4, clinical trials of CBD in patients receiving enzyme-inducing AEDs, such as carbamazepine or phenytoin, will require detailed pharmacokinetic studies.

The reason so many people are interested in cannabis products that don’t make them high, proponents say, is that CBD helps with everything from pain and nausea to rheumatoid arthritis, cancer, Crohn’s disease, and dementia. CBD is anti-inflammatory, anti-anxiety, antibacterial, immunosuppressive, and more, says Joseph Cohen, DO, a cannabis doctor in Boulder, CO.
A survey of patients seen in a tertiary epilepsy center found that 21% of patients admitted to using marijuana in the last year, and 24% of patients believed marijuana to be effective for their seizures (10). While interesting, this anecdotal observation does not rise to the level of evidence needed to evaluate a potential new therapeutic modality.